Astellas Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ASTELLAS, and when can generic versions of ASTELLAS drugs launch?
ASTELLAS has thirty-seven approved drugs.
There are twenty-five US patents protecting ASTELLAS drugs. There is one tentative approval on ASTELLAS drugs.
There are four hundred and thirty-three patent family members on ASTELLAS drugs in forty-two countries and sixty-five supplementary protection certificates in nineteen countries.
Summary for Astellas
International Patents: | 433 |
US Patents: | 25 |
Tradenames: | 21 |
Ingredients: | 16 |
NDAs: | 37 |
Patent Litigation for Astellas: | See patent lawsuits for Astellas |
Drugs and US Patents for Astellas
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | CRESEMBA | isavuconazonium sulfate | POWDER;INTRAVENOUS | 207501-001 | Mar 6, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-002 | Aug 4, 2020 | RX | Yes | Yes | 8,183,274 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astellas | ARISTOCORT A | triamcinolone acetonide | CREAM;TOPICAL | 083017-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Astellas
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astellas | CRESEMBA | isavuconazonium sulfate | CAPSULE;ORAL | 207500-001 | Mar 6, 2015 | 7,459,561 | ⤷ Try a Trial |
Astellas | ASTAGRAF XL | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 204096-002 | Jul 19, 2013 | 6,440,458 | ⤷ Try a Trial |
Astellas | VESICARE | solifenacin succinate | TABLET;ORAL | 021518-001 | Nov 19, 2004 | 6,017,927*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 40 mg | ➤ Subscribe | 2016-08-31 |
➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-18 |
➤ Subscribe | Injection | 0.08 mg/mL, 5 mL vial | ➤ Subscribe | 2012-04-10 |
➤ Subscribe | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg | ➤ Subscribe | 2013-11-15 |
➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-16 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2009-04-08 |
International Patents for Astellas Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Serbia | 56501 | ⤷ Try a Trial |
Japan | WO2010128659 | ⤷ Try a Trial |
Australia | 2018200316 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Astellas Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2428508 | LUC00147 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: GILTERITINIB OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1399 20191028 |
2428508 | C202030004 | Spain | ⤷ Try a Trial | PRODUCT NAME: GILTERITINIB O UNA SAL DEL MISMO NOMBRE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1399; DATE OF AUTHORISATION: 20191024; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1399; DATE OF FIRST AUTHORISATION IN EEA: 20191024 |
1280795 | 92939 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ISAVUCONBAZOLE EN TANT QUE SULFATE D'ISAVUCONAZONIUM OU EN TANT QUE SEL D'ISAVUCONAZONIUM AVEC TOUT AUTRE ANION PHARMACEUTIQUEMENT ACCEPTABLE, OPTIONNELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151019 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.